Commission Recommendations
MedPAC makes recommendations to the Congress and to the Secretary of Health and Human Services on issues affecting the administration of the Medicare program. With its recommendations, the Commission strives to improve the delivery of care, while ensuring financial stability and maximizing value for the program. After extensive analysis and evaluation, our recommendations are discussed and voted on by Commissioners in our public meetings. Recommendations are typically published in two main reports, released in March and June of each year.
| Recommendations | Topic(s) | Publication |
|---|---|---|
Ambulatory surgical center servicesThe Commission reiterates its March 2022 recommendation that the Secretary require ambulatory surgical centers to report cost data. |
|
|
Outpatient dialysis servicesFor calendar year 2024, the Congress should update the 2023 Medicare end-stage renal disease prospective payment system base rate by the amount determined under current law. |
|
|
Ambulatory surgical center services (1)For calendar year 2023, the Congress should eliminate the update to the 2022 Medicare conversion factor for ambulatory surgical centers. |
|
|
Ambulatory surgical center services (2)The Secretary should require ambulatory surgical centers to report cost data. |
|
|
Outpatient dialysis servicesFor calendar year 2023, the Congress should update the 2022 Medicare end-stage renal disease prospective payment system base rate by the amount determined under current law. |
|
|
Ambulatory surgical center services (1)For calendar year 2022, the Congress should eliminate the update to the 2021 Medicare conversion factor for ambulatory surgical centers. |
|
|
Ambulatory surgical center services (2)The Secretary should require ambulatory surgical centers to report cost data. |
|
|
Outpatient dialysis servicesFor calendar year 2022, the Congress should eliminate the update to the 2021 Medicare end-stage renal disease prospective payment system base rate. |
|
|
Improving Medicare’s end-stage renal disease prospective payment system (1)The Congress should direct the Secretary to eliminate the end-stage renal disease prospective payment system’s transitional drug add-on payment adjustment for new drugs in an existing end-stage renal disease functional category. |
|
|
Improving Medicare’s end-stage renal disease prospective payment system (2)The Secretary should replace the current low-volume and rural payment adjustments in the end-stage renal disease prospective payment system with a single adjustment for dialysis facilities that are isolated and consistently have low volume, where low-volume criteria are empirically derived. |
|